Agenus Inc. (NASDAQ:AGEN) has received a consensus rating of “Buy” from the seven brokerages that are currently covering the firm. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $11.20.

Several equities analysts recently commented on AGEN shares. Jefferies Group restated a “buy” rating on shares of Agenus in a research report on Tuesday, August 23rd. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Agenus in a research report on Sunday, July 31st. Maxim Group reiterated a “buy” rating and issued a $7.00 price objective on shares of Agenus in a research report on Thursday, July 28th. Finally, Zacks Investment Research downgraded Agenus from a “buy” rating to a “hold” rating in a research report on Wednesday, September 28th.

In other news, Director Ulf Wiinberg bought 30,000 shares of the stock in a transaction dated Tuesday, September 6th. The stock was bought at an average cost of $6.29 per share, with a total value of $188,700.00. Following the purchase, the director now owns 30,000 shares of the company’s stock, valued at $188,700. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 7.60% of the stock is owned by insiders.

Several large investors have recently added to or reduced their stakes in the stock. RTW Investments LLC boosted its stake in Agenus by 70.5% in the third quarter. RTW Investments LLC now owns 4,141,644 shares of the company’s stock valued at $29,737,000 after buying an additional 1,712,495 shares during the period. Credit Suisse AG boosted its stake in Agenus by 26.5% in the third quarter. Credit Suisse AG now owns 51,933 shares of the company’s stock valued at $373,000 after buying an additional 10,888 shares during the period. Candriam Luxembourg S.C.A. boosted its stake in Agenus by 13.1% in the third quarter. Candriam Luxembourg S.C.A. now owns 517,700 shares of the company’s stock valued at $3,717,000 after buying an additional 60,000 shares during the period. Highbridge Capital Management LLC purchased a new stake in Agenus during the third quarter valued at approximately $418,000. Finally, D. E. Shaw & Co. Inc. purchased a new stake in Agenus during the third quarter valued at approximately $1,943,000. 40.88% of the stock is owned by institutional investors.

Shares of Agenus (NASDAQ:AGEN) opened at 4.90 on Thursday. The stock’s market capitalization is $426.92 million. Agenus has a one year low of $2.61 and a one year high of $7.49. The stock’s 50 day moving average price is $5.51 and its 200 day moving average price is $5.21.

Agenus (NASDAQ:AGEN) last posted its earnings results on Thursday, October 27th. The company reported ($0.47) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.18. The company had revenue of $4.45 million for the quarter, compared to the consensus estimate of $6.15 million. Agenus had a negative return on equity of 359.98% and a negative net margin of 472.80%. On average, analysts forecast that Agenus will post ($1.45) EPS for the current year.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

5 Day Chart for NASDAQ:AGEN

Receive News & Stock Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related stocks with our FREE daily email newsletter.